In Brief: ICN Pharmaceuticals/SmithKline
This article was originally published in The Tan Sheet
Executive Summary
ICN Pharmaceuticals/SmithKline: ICN to acquire rights to market 39 Rx and OTC drugs in Eastern Europe, Asia, Australia and Africa from SmithKline Beecham for $45.5 mil. in cash and stock, the Costa Mesa, Calif.-based company announces. SB will retain the rights to the products in Western Europe and North America. ICN, which recently acquired 10 Rx products from Hoffmann-La Roche, claims the acquisition is "yet another important step in the development of ICN's international strategy of entering emerging markets with a series of core products"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning